Optimal glycaemic control during caesarean section provided by sensor-augmented pump therapy with predictive low-glucose suspend function

Excerpt

Sensor-augmented pump therapy (SAP) has proven to improve glycaemic control and to reduce the frequency of hypoglycaemia in patients with type 1 diabetes (T1D). Different types of automation of insulin delivery according to the sensor readings have been implemented. The predictive low-glucose suspend function (PLGS) uses a prediction algorithm to stop insulin infusion when a sensor value below a specified target is expected to be reached. Due to the proven benefit in randomised clinical trials, SAP with PLGS is increasingly used in clinical practice [1]. As more T1D patients are using this therapy, its presence in hospital settings, including emergency services and surgery, is being more frequently reported and evaluated [2, 3]. Also, maternal and perinatal outcomes have been found to improve with the use of continuous glucose monitoring (CGM), associated both with pump therapy and with multiple daily insulin injections [4]. …